---
title: Markin vs building it in-house: what a team can realistically ship
url: https://markin.ai/compare/markin-vs-in-house-data-science
kind: vs
description: Building a decision layer in-house is possible and sometimes right. An honest comparison of throughput, cost, ownership and time to a verified number.
updated: 2026-08-20
---

# Markin vs building it in-house: what a team can realistically ship

> An in-house team can build a decision layer: models, feature store, orchestration, experiment framework and activation. The question is throughput. Markin generates, sizes, launches and reads hypotheses continuously, so the same team supervises hundreds of tested ideas per quarter instead of shipping a handful.

## In short

- In-house data science and growth: What can we build and ship with the people we have? Output: Models, scores, dashboards and a queue of shipped experiments.
- Markin: Which opportunity is worth acting on, for whom, and what did it return? Output: A ranked, sized action per customer, executed through your stack.
- The queue is ordered by who asked, because nothing sizes ideas in money.
- It multiplies what the team can supervise, and it takes over the parts nobody enjoys: pipelines, sizing, control-group hygiene and retirement.

## The short answer

This is the honest comparison, because the alternative to Markin is usually not another vendor, it is a roadmap. In-house wins on control and on domain judgement. Markin wins on throughput and on time to a verified number, and it makes your team the reviewers rather than the builders.

## The two options

**In-house data science and growth**, Your own analysts, scientists and engineers building models, pipelines, experiment frameworks and activation on top of the warehouse.

Choose it when the domain is unusual, the team is already staffed for it, and control matters more than speed.

- Full control
- Domain knowledge
- Bounded by headcount

**Markin**, The same operating loop, run continuously by an autonomous system your team supervises: hypothesis, sizing, design, execution, holdout read, scale or retire.

Choose it when the backlog is measured in quarters and the base is large enough that untested ideas are expensive.

- Hundreds of tested ideas
- 90 days to a number
- Your team reviews

## Line by line

| Dimension | Markin | In-house data science and growth |
| --- | --- | --- |
| What it is | An autonomous growth-science team: it investigates why revenue per customer is stuck and acts on what it finds. | A team, a warehouse and a roadmap. |
| What it decides | Which commercial opportunity deserves to exist for each customer this week, what it is worth, and when the right answer is to do nothing. | Whatever the team has had time to build a model and a pipeline for. |
| Where hypotheses come from | Generated by Markin from customer, product, pricing and technical-health data, then sized before anyone builds anything. | Proposed in planning, filtered by seniority and capacity. |
| Scope of action | Marketing, product, pricing and technical-health hypotheses, arbitrated against each other in one queue. | As broad as the team's remit, in practice narrowed to what is shippable this quarter. |
| How the work reaches the customer | Written back into the systems you already run, as attributes, events or API calls. Markin does not add a new customer-facing surface. | Custom integrations built and maintained per channel. |
| How impact is proven | A randomised holdout on every decision. The reported number is incremental revenue and ARPU, not attributed conversions. | Good when the team insists on holdouts; often the first thing dropped under deadline. |
| Where the data sits | Reads context where it already lives, warehouse, CDP, product and billing systems. No new system of record. | Your warehouse, with a feature store to build and maintain. |
| Governance and control | Every action carries its hypothesis, its expected value, its guardrails and its control group, reviewable before launch. | Whatever the team documents. |
| Time to a verified number | One revenue theme, one channel, one holdout: a defensible incremental number inside 90 days. | Typically two to four quarters before the first defensible incremental number. |
| Best fit | Large B2C bases where the constraint is how many good hypotheses get tested, not how many messages get sent. | Unusual domains, strong existing platform teams, control-first organisations. |

## What each layer is

**In-house data science and growth**, Your own team building models, pipelines, experiments and activation on the warehouse.

Answers: What can we build and ship with the people we have?

**Markin**, An autonomous growth-science team running the same loop continuously, under human review.

Answers: Which opportunity is worth acting on, for whom, and what did it return?

## Side by side

|  | In-house data science and growth | Markin |
| --- | --- | --- |
| Question it answers | What can we build and ship with the people we have? | Which opportunity is worth acting on, for whom, and what did it return? |
| Primary input | Warehouse data, roadmap priorities, stakeholder requests. | The same warehouse, plus margins, constraints and experiment history. |
| Primary output | Models, scores, dashboards and a queue of shipped experiments. | A ranked, sized action per customer, executed through your stack. |
| Usual owner | Data science, analytics engineering and growth. | Growth, data science and revenue leadership, as reviewers. |
| How it's measured | Model quality and, where holdouts survive, incremental lift. | Incremental revenue and ARPU against a randomised holdout. |

## What In-house data science and growth does better

- **Domain judgement is yours, not ours.** Your team knows which segments are politically untouchable, which margins are wrong in the warehouse and which promise the regulator will not accept. That knowledge is not replaceable, which is why Markin puts humans in the review loop rather than around it.
- **Control and portability.** Building in-house means no vendor dependency, models you can inspect line by line, and a platform that can be repurposed. Those are real advantages and some organisations should pay for them.
- **Sometimes the first version is enough.** If two propensity models and a weekly export move the number, build them. Markin earns its place when the constraint is the twentieth hypothesis, not the second.

## Which one to pick

**Choose Markin if**

- The analysis backlog is longer than the roadmap and growing.
- You want hundreds of sized, tested hypotheses per quarter, not a handful.
- You need a defensible incremental number this quarter.
- Your scientists should be reviewing decisions, not maintaining pipelines.
- Growth questions span marketing, pricing, product and technical health.

**Choose building in-house if**

- Your domain is unusual enough that generic hypothesis generation would miss.
- You already have a staffed platform team and a working experiment framework.
- Policy requires every model to be owned and inspectable internally.
- The base is small enough that a few well-chosen models cover it.
- There is no appetite for another vendor in the stack this year.

## The bottleneck is throughput, not talent

Strong teams do not fail on model quality. They fail because each idea costs weeks of pipeline, integration and stakeholder work, so only the safest ideas get tested and the long tail of smaller, compounding wins is never examined.

- The queue is ordered by who asked, because nothing sizes ideas in money.
- Integration work dominates: the same activation is rebuilt per channel.
- Holdouts are the first casualty of a deadline, so results become arguable.
- Winners are rarely re-read, so decayed models keep running.

## Where Markin fits

Markin does not replace the team. It multiplies what the team can supervise, and it takes over the parts nobody enjoys: pipelines, sizing, control-group hygiene and retirement.

- **Your people review.** Every hypothesis carries its evidence, its expected value and its guardrails.
- **Pipelines stop being the job.** Activation into existing systems is handled once, not per idea.
- **Discipline by default.** Holdouts and re-reads are structural, not optional.

Next: [Revenue Discovery](https://markin.ai/solutions/revenue-discovery)

## When Markin is not the right answer

- You want a tool your team will operate as a library: Markin runs a loop, not a notebook.
- The base is too small for controlled measurement.
- Data foundations are not yet reliable enough to size opportunities in money.

## FAQ

**Does Markin replace our data science team?**

No, and the deployments that work best have strong teams. Markin changes what they spend time on: reviewing sized hypotheses and owning judgement calls instead of building pipelines and chasing integrations.

**Could we build this ourselves?**

Yes. Most of the components exist. The realistic cost is two to four quarters of platform work before the first defensible incremental number, plus ongoing maintenance of activation and experiment hygiene.

**What does in-house do better?**

Domain judgement, full control and inspectability of models, and no vendor dependency.

**How is throughput actually different?**

Markin generates and sizes hypotheses continuously and only escalates the ones that clear a value threshold, so review capacity, not build capacity, becomes the limit.

**How is Markin different from the decisioning or AI already inside in-house data science and growth?**

A decisioning engine ranks actions a human already defined, inside the campaign surface it was given. Markin forms the hypotheses itself,  marketing, product, pricing or a technical anomaly holding growth back, sizes them, executes them inside in-house data science and growth and your product surfaces, and reads each one against a randomised holdout. It behaves like a data science and growth team, not like an optimiser.

**Does Markin only test messages and offers?**

No. Anything a human growth scientist would investigate is in scope: onboarding friction, feature adoption, pricing and packaging, dunning, and technical health issues such as a checkout error rate or a broken deeplink quietly killing conversion. Marketing is one of four hypothesis domains, not the boundary.

**What is the business case for adding Markin on top of in-house data science and growth?**

On a large B2C base, a small move in ARPU is a large number in absolute terms, because it applies to the whole installed base every month rather than to a campaign. Across Markin deployments the verified range on treated cohorts is +17% to +35% ARPU against a randomised holdout. The point is not more messages: it is finding the highest-value action per customer, launching it, and proving it against control before it scales.

**How long before it pays for itself?**

First sized opportunities are in test within six weeks and the first holdout-verified result lands inside 90 days. Payback depends on your base, margin and programme cost, the calculator on this page computes it from your own numbers, after applying the 20% to 40% haircut BCG finds when next-best-action programmes are incrementality-tested.

Source: https://markin.ai/compare/markin-vs-in-house-data-science